bluebird bio Inc (BLUE) : Artal Group S.a. reduced its stake in bluebird bio Inc by 10.0% during the most recent quarter end. The investment management company now holds a total of 450,000 shares of bluebird bio Inc which is valued at $25,560,000 after selling 50,000 shares in bluebird bio Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.bluebird bio Inc makes up approximately 0.53% of Artal Group S.a.’s portfolio.
Other Hedge Funds, Including , United Services Automobile Association reduced its stake in BLUE by selling 310 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 33,220 shares of BLUE which is valued at $1,886,896. bluebird bio Inc makes up approx 0.01% of United Services Automobile Association’s portfolio. Thompson Davis sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 33 shares of BLUE which is valued $1,830.Zurcher Kantonalbank (zurich Cantonalbank) boosted its stake in BLUE in the latest quarter, The investment management firm added 1,549 additional shares and now holds a total of 49,767 shares of bluebird bio Inc which is valued at $2,956,657. bluebird bio Inc makes up approx 0.04% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio. Tarbox Group sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 9 shares of BLUE which is valued $515. Fny Managed Accounts sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 2,000 shares of BLUE which is valued $112,240.
bluebird bio Inc opened for trading at $55 and hit $55.55 on the upside on Tuesday, eventually ending the session at $54.91, with a gain of 0.37% or 0.2 points. The heightened volatility saw the trading volume jump to 8,38,357 shares. Company has a market cap of $2,041 M.
On the company’s financial health, bluebird bio Inc reported $-1.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-1.50. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $2.01 million. The company’s revenue was down -68.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-1.57 EPS.
Many Wall Street Analysts have commented on bluebird bio Inc. Shares were Reiterated by Maxim Group on Aug 4, 2016 to “Buy” and Lowered the Price Target to $ 85 from a previous price target of $105 .bluebird bio Inc was Initiated by Cantor Fitzgerald to “Hold” on Jun 3, 2016.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.